Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Tuesday, 19 September 2023, 21:00 HKT/SGT
Share:
    

Source: Syndesis Health
Syndesis Health and InSyBio Partner in Predictive Modelling and Biomarker Discovery

InSyBio, a leading biotechnology company that has developed a suite of advanced AI tools for biomarker discovery in clinical and multi-omics data, has announced a strategic partnership with Syndesis Health, a leader in global real-world evidence. The partnership aims to leverage the clinical and genomic data on Syntium, Syndesis' data platform of global healthcare data, to accelerate research and development in several therapeutic areas, including cardiovascular health, oncology, and rare diseases.

The importance of biomarkers

Biomarkers are body characteristics that can be measured, such as the biological molecules found in bodily fluids or tissues, including DNA, antibodies, proteins, or other smaller molecules. They are necessary to predict the effectiveness of drugs and patient outcomes; however, biomarker discovery is a very complex and costly process that often results in poor or inaccurate outcomes due to the use of disparate tools and datasets, and the high complexity of high-throughput -omics data.

InSyBio's platform simplifies and accelerates the process of biomarker discovery by providing a single, highly accurate, and effective processing pipeline that uses machine learning to analyze biodata. Syntium's longitudinal datasets, which include clinical, genomic, and other data, are ideal for applying InSyBio's suite of tools in biomarker discovery. Combining Syntium data with InSyBio's platform will create a unique opportunity for biopharma and diagnostic companies to uncover breakthrough discoveries with the potential to vastly improve global patient outcomes.

"Precision medicine is still in its infancy and many patients are misdiagnosed or do not get the most beneficial treatment for them. The wealth of Syntium's data sets when harnessed by our automatic AI-driven technology holds the potential to upend the medical field practices, and highly impact overall healthcare quality at national and international levels. We are looking forward to working with the innovative team of Syndesis Health," said Labros Digonis, InSyBio CEO.

"We are incredibly excited to embark on this partnership with InSyBio to enable biomarker discovery for cutting-edge healthcare innovation," said Josh Sutton, Syndesis Health CEO. "Together we seek to raise the bar for global health research and innovation in service of patients worldwide."

About Syndesis Health

Syndesis Health is the data and technology catalyst to a multi-continent network of healthcare and life sciences organizations. Its primary aim is to enhance global health outcomes and equity through its secure data platform, Syntium, and the Syndesis Health Network, a member community promoting research collaboration, information sharing, and access to common tools.

About InSyBio

InSyBio is an international pioneer biotechnology company revolutionizing the medical �eld through targeted biomarker discovery, highly accurate predictive analytics and the development of personalization tests for drugs. Its solutions provide the R&D departments of Pharma and Research Institutes with the means to meet their most challenging research and innovation goals. This is done through a sophisticated, software-as-a-service, machine learning platform, which comprehensively integrates multi-omics and clinical data, thus reducing the number of samples and additional validation experiments needed.

Contact Information

Leah Patterson 
Chief Marketing Officer 
leah.patterson@syndesis.com 
+1.646.274.1420

 




Topic: Press release summary
Source: Syndesis Health

Sectors: BioTech, Healthcare & Pharm
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Latest Press Releases
CITIC Telecom CPC's 'AI+ Coud Network Security' Innovation Continues to Attain Recognition for Unmatched Capabilities

  
July 13, 2024 00:05 HKT/SGT
MooFest 2024 by Moomoo Singapore and AlphaInvest Receives Massive Turnout  
July 12, 2024 19:30 HKT/SGT
TOYOTA GAZOO Racing faces a new challenge with full strength  
Friday, July 12, 2024 6:15:00 PM
MHI Selected for Inclusion in Two ESG Investment Indices: FTSE Blossom Japan Index and FTSE Blossom Japan Sector Relative Index  
Friday, July 12, 2024 3:13:00 PM
TGR Announces Upgraded GR86 and Limited Special-edition Model  
Friday, July 12, 2024 1:48:00 PM
Asia-Pacific youth and Habitat for Humanity join hands to implement solutions for decent housing  
July 12, 2024 13:06 HKT/SGT
"LEQEMBI" (Lecanemab) Approved for the Treatment of Alzheimer's Disease in Israel  
Friday, July 12, 2024 11:56:00 AM
KSL Capital Partners & Soneva Resorts: A Cautionary Tale of Due Diligence  
July 12, 2024 08:34 HKT/SGT
Q2 Metals Updates Private Placement  
July 12, 2024 08:00 HKT/SGT
Fonos Sees Monthly Active Users Increase to 6X with CleverTap's Personalized Engagement  
July 11, 2024 15:00 HKT/SGT
More Press release >>
 Events:
More >>
 News Alerts
Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: